CPA
NMRA icon

Capital Performance Advisors’s Neumora Therapeutics NMRA Stock Holding History

Capital Performance Advisors’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-11
Closed -$145 – 1783
2024
Q3 		$145 Buy
+11
New +$128 ﹤0.01% 2630

Other funds holding NMRA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return

Capital Performance Advisors's NMRA Position: Q4 2024 in Review

Capital Performance Advisors sold out of Neumora Therapeutics (NMRA) in Q4 2024, closing a stake of 11 shares — an estimated $145 sold.

Capital Performance Advisors first reported a position in NMRA in Q3 2024 and held it in 1 quarter. The position peaked at $145 in Q3 2024. 134 funds tracked by Wall St. Rank hold NMRA as of Q4 2024.

  • Capital Performance Advisors reported no remaining Neumora Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 11 Neumora Therapeutics shares in Q4 2024, an estimated $145.
  • Capital Performance Advisors first reported a position in Neumora Therapeutics in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Neumora Therapeutics position peaked at $145 in Q3 2024.
  • 134 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.